Undetectable MRD and Extended PFS More Common with MRD-guided Ibrutinib-Venetoclax than with Ibrutinib Alone or FCR Regimen Among Patients with CLL By Ogkologos - October 13, 2025 93 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the FLAIR study Source RELATED ARTICLESMORE FROM AUTHOR The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer ESMO Welcomes Launch of Health Package Introducing EU Measures That Can Boost Innovation in Oncology and Help Prevent New Cancer Cases MOST POPULAR The Pesticide Chemical Responsible For Mass Bee Die-Offs Is Killing Birds... August 20, 2020 ESMO Immuno-Oncology Virtual Congress 2020 November 30, 2020 Holidays, Traditions and Grief December 21, 2020 Adjuvant Dabrafenib Plus Trametinib Associated with Better RFS and DMFS than... July 9, 2024 Load more HOT NEWS Mental Health Awareness for Health Care Providers The Frontline Oncology Workforce Unites to Reduce the Burden of Cancer... Cancer in My Community: Working Toward Early Diagnosis for Children With... Some Women Avoid Breast Cancer Screening After False-Positive Mammogram Results
